These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 27834733

  • 1. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
    Doll S, Urisman A, Oses-Prieto JA, Arnott D, Burlingame AL.
    Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
    [Abstract] [Full Text] [Related]

  • 2. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X, Wu S, Zhang J, Li M, Xu F, Wang A, Lei Y, Zhu G.
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [Abstract] [Full Text] [Related]

  • 3. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ.
    Neuro Oncol; 2022 Sep 01; 24(9):1471-1481. PubMed ID: 35287169
    [Abstract] [Full Text] [Related]

  • 4. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM, Pinto N, Khan MI, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Nichols AC.
    Oral Oncol; 2018 Sep 01; 84():95-103. PubMed ID: 30115483
    [Abstract] [Full Text] [Related]

  • 5. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB.
    Mol Cancer Res; 2016 Oct 01; 14(10):1019-1029. PubMed ID: 27422710
    [Abstract] [Full Text] [Related]

  • 6. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.
    J Clin Oncol; 2011 Dec 01; 29(34):4482-90. PubMed ID: 22025148
    [Abstract] [Full Text] [Related]

  • 7. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.
    Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB.
    J Neurooncol; 2014 Mar 01; 117(1):53-65. PubMed ID: 24473683
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
    Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S.
    Brain Tumor Pathol; 2012 Oct 01; 29(4):183-91. PubMed ID: 22790483
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA, Miller JJ, Tummala SS, Penson T, Iafrate AJ, Juratli TA, Cahill DP.
    Acta Neuropathol Commun; 2018 Oct 17; 6(1):106. PubMed ID: 30333046
    [Abstract] [Full Text] [Related]

  • 16. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
    Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J.
    J Biol Chem; 2015 Aug 07; 290(32):19387-401. PubMed ID: 25998128
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
    Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, Schoppmann SF, Tchorbanov A, Streubel B, Tuettenberg J, Guentchev M.
    Cancer; 2014 Aug 15; 120(16):2440-7. PubMed ID: 24771584
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.